113 related articles for article (PubMed ID: 16234556)
1. C225 and PDT combination therapy for ovarian cancer: the play's the thing.
Cengel KA; Hahn SM; Glatstein E
J Natl Cancer Inst; 2005 Oct; 97(20):1488-9. PubMed ID: 16234556
[No Abstract] [Full Text] [Related]
2. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells.
Abu-Yousif AO; Moor AC; Zheng X; Savellano MD; Yu W; Selbo PK; Hasan T
Cancer Lett; 2012 Aug; 321(2):120-7. PubMed ID: 22266098
[TBL] [Abstract][Full Text] [Related]
4. Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy.
Weyergang A; Selbo PK; Berg K
Biochim Biophys Acta; 2013 Mar; 1830(3):2659-70. PubMed ID: 23671927
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
Morrison J; Briggs SS; Green NK; Thoma C; Fisher KD; Kehoe S; Seymour LW
Hum Gene Ther; 2009 Mar; 20(3):239-51. PubMed ID: 19257852
[TBL] [Abstract][Full Text] [Related]
6. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.
Cascales Campos PA; Gil Martínez J; Galindo Fernández PJ; Gil Gómez E; Martínez Frutos IM; Parrilla Paricio P
Eur J Surg Oncol; 2011 Jun; 37(6):543-8. PubMed ID: 21489742
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of hematoporphyrin-herceptin photoimmunoconjugate for photoimmunotherapy].
Chen L; Luo RC; Li LB; Yan X; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):355-7. PubMed ID: 16546747
[TBL] [Abstract][Full Text] [Related]
8. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
[TBL] [Abstract][Full Text] [Related]
9. [Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data].
Salle B; Gilly FN; Carry PY; Sayag A; Brachet A; Braillon G
J Gynecol Obstet Biol Reprod (Paris); 1993; 22(4):369-71. PubMed ID: 8360435
[TBL] [Abstract][Full Text] [Related]
10. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
[TBL] [Abstract][Full Text] [Related]
11. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.
Shaheen RM; Ahmad SA; Liu W; Reinmuth N; Jung YD; Tseng WW; Drazan KE; Bucana CD; Hicklin DJ; Ellis LM
Br J Cancer; 2001 Aug; 85(4):584-9. PubMed ID: 11506500
[TBL] [Abstract][Full Text] [Related]
12. Photoimmunotherapy and ovarian cancer: an improbable fiction or a palpable hit?
Tochner ZA; Hahn S; Glatstein E
J Natl Cancer Inst; 1999 Sep; 91(18):1526-7. PubMed ID: 10491420
[No Abstract] [Full Text] [Related]
13. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
Cascales Campos P; Gil J; Parrilla P
Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
[TBL] [Abstract][Full Text] [Related]
14. Phototoxicity of Hemoporfin to ovarian cancer.
Song K; Kong B; Qu X; Li L; Yang Q
Biochem Biophys Res Commun; 2005 Nov; 337(1):127-32. PubMed ID: 16182254
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
Sato N; Saga Y; Mizukami H; Wang D; Fujiwara H; Takei Y; Machida S; Ozawa K; Suzuki M
Oncol Rep; 2012 May; 27(5):1336-40. PubMed ID: 22246397
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions.
Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Ramakrishna V; Bolhuis RL; Colnaghi MI; Bolis G
J Hematother; 1995 Oct; 4(5):423-7. PubMed ID: 8581379
[TBL] [Abstract][Full Text] [Related]
17. The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment.
Holubec L; Polivka J; Safanda M; Karas M; Liska V
Anticancer Res; 2016 Sep; 36(9):4421-6. PubMed ID: 27630277
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
19. [Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Baba T; Mandai M; Fujii S
Nihon Rinsho; 2004 Oct; 62 Suppl 10():467-70. PubMed ID: 15535289
[No Abstract] [Full Text] [Related]
20. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Schultes BC; Smith LM; Nicodemus CF
Clin Cancer Res; 2007 Jul; 13(13):4026; author reply 4026-7. PubMed ID: 17606738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
